Join us for the next webinar in the
Industrializing Gene Therapy
- 60 Minutes
Select the date and time for the webinar that best fits your schedule.
Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.
Participants will learn:
- The manufacturing challenges facing the viral vector industry
- The advantages of an integrated manufacturing solution
- How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom
Dr. Clive Glover
Director, Cell & Gene Therapy
Dr Clive Glover is the Director of Cell & Gene Therapy at Pall Biotech. Clive leads Pall’s cell and gene therapy business. He has over 15 years of experience in cell and gene therapy. His work has been published in numerous scientific journals, and he has presented at many conferences. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia. When not at work, Clive spends a lot of time singing in Welsh choruses and hiking the Welsh hills.
Global Product Manager, Integrated Solutions
Jeremy Rautenbach is a Global Product Manager for Integrated Solutions at Pall Biotech. He has worked on several activities focusing on industrializing bioprocesses in a way that brings life-saving therapies to market faster.
In a previous role, he was responsible for driving and managing new product development. He holds an MS in mechanical engineering from the MIT School of Engineering and an MBA from the MIT Sloan School of Management. His work on improving production yields of biopharmaceutical filter media earned him the best thesis in his MIT program, as voted by faculty.
When not working, Jeremy enjoys spending time with family either offshore fishing or taking long walks in the countryside.
Dr. Joseph Rininger
Latham BioPharm Group
Director, Cell & Gene Therapy
Dr. Rininger possesses over twenty years of experience in basic biomedical research and biopharmaceutical product development, manufacturing and program management with an emphasis on AAV-based gene therapy and vaccines. Prior to joining Latham Biopharm Group (LBG), he worked at several small and mid-size biotechnology companies, growing into positions of increased responsibility at each organization. At Protein Science Corporation (PSC), he served as Director of Business Development and worked to secure and then manage new biologic contract manufacturing projects, grew an established research product business unit. In this role, he successfully oversaw project teams and the development of upstream and downstream processes for transfer to cGMP manufacturing of two biologics and four vaccine candidates to enter first-in-human trials. In addition, he licensed PSC’s technology for AAV manufacturing and supported regulatory submissions for Glybera, the first AAV gene therapy approved in the western world. Dr. Rininger subsequently served as the program manager of a ~$150M HHS/BARDA contract for the advanced development and commercialization of Flublok®, the first approved recombinant hemagglutinin-based subunit vaccine for seasonal influenza. At LBG, Dr. Rininger leads product development engagements with gene and cell therapy companies and service providers and is actively supporting multiple early stage programs in this sector to advance them to Phase 1-2 clinical development. Dr. Rininger earned his Ph.D. from Cornell University in Toxicology and a B.S. in Marine Biology with a Concentration in Biotechnology from Fairleigh Dickinson University. He has several awarded and pending patents and is well published in industry magazines and peer-reviewed journals.
Director, Sales Engineering
Peter has over 14 years of experience in pharmaceutical and biopharmaceutical industries. Peter held various technical roles in process solutions for the biotech industry prior to moving into management positions in technical and sales roles. He has extensive knowledge of bioprocess manufacturing and helped design new facilities and retrofit existing facilities with single use technologies. Peter joined G-CON Manufacturing in 2016 where he now consults with clients in the design of their facilities utilizing G-CON’s prefabricated autonomous clean rooms.
Peter received his Bachelor of Science in Chemical Engineering and a Minor in Biomedical Engineering from Cornell University. He received is M. Eng in Chemical Engineering from Cornell University.
All fields required